4 de octubre de 2016 / 11:22 / en un año

BRIEF-Sarepta and Summit enter into agreement for European rights to utrophin modulator pipeline

Oct 4 (Reuters) - Summit Therapeutics Plc :

* Summit receives $40 million upfront, with potential future ezutromid-related milestone payments totalling up to $522 million plus royalties

* Sarepta also receives option for Latin American rights

* As part of agreement, Sarepta also obtains an option to license latin american rights to Summit’s utrophin modulator pipeline

* If Sarepta elects to exercise option for Latin American rights, co would be entitled to additional fees, milestones and royalties

* Sarepta and Summit to share research and development costs

* Sarepta also receives option for Latin American rights

* Sarepta Therapeutics and summit enter into exclusive license and collaboration agreement for european rights to summit’s utrophin modulator pipeline for the treatment of duchenne muscular dystrophy

* Sarepta, co will share specified utrophin modulator-related research and development costs at a 45/55 pct split, respectively Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below